1. Introduction
Precision medicine aims to tailor therapy to the biological characteristics of each patient rather than relying solely on clinical phenotype. The molecular basis of this approach rests on a detailed understanding of the DNA, RNA, protein, and epigenetic landscapes that drive disease. By integrating these layers of information, clinicians can identify actionable targets, avoid ineffective treatments, and anticipate resistance mechanisms.
2. Genomic Profiling
Highthroughput sequencing technologies, particularly nextgeneration sequencing (NGS), have made it possible to interrogate the entire genome or selected gene panels within a single diagnostic test. Key concepts include:
- Somatic mutations alterations acquired by tumor cells that can be targeted (e.g., EGFR, BRAF).
- Germline variants inherited changes influencing drug metabolism (e.g., TPMT, UGT1A1).
- Copynumber variations amplifications or deletions that affect gene dosage.
- Structural rearrangements fusions such as ALKEML4 in lung cancer.
Interpretation frameworks such as the AMP/ASCO/CAP guidelines categorize variants as tier IIV based on clinical relevance, providing a systematic method to prioritize therapeutic options.
3. Proteomics and Phosphoproteomics
While genomics reveals potential drivers, protein expression and posttranslational modifications (PTMs) determine functional output. Massspectrometrybased proteomics quantifies thousands of proteins simultaneously, allowing clinicians to:
- Validate that a mutated gene is translated into an active oncoprotein.
- Identify activated signaling pathways through phosphosite analysis.
- Detect druginduced changes that signal response or resistance.
For example, high HER2 protein levels measured by immunohistochemistry (IHC) or by targeted proteomics confirm eligibility for trastuzumab therapy even when the gene is not amplified.
4. Epigenetic Modifiers
Epigenetic alterationsincluding DNA methylation, histone modifications, and noncoding RNAsmodify gene expression without changing the underlying sequence. Clinically relevant epigenetic markers include:
- MGMT promoter methylation in glioblastoma, predicting response to temozolomide.
- BRD4 inhibitors targeting acetylhistone readers in certain leukemias.
- MicroRNA signatures that influence chemotherapy sensitivity.
Assays such as bisulfite sequencing and chromatin immunoprecipitation sequencing (ChIPseq) are increasingly incorporated into diagnostic pipelines.
5. Predictive Biomarkers
A biomarker is any measurable indicator of a biological state that predicts therapeutic benefit. The most widely used categories are:
| Biomarker Type | Example | Clinical Utility |
|---|---|---|
| Genetic | KRAS G12C | Eligibility for sotorasib |
| Protein | PDL1 expression | Guides checkpoint inhibitor use |
| Metabolomic | 2hydroxyglutarate | Identifies IDHmutant gliomas |
| Epigenetic | MLH1 promoter methylation | Predicts response to immune checkpoint blockade |
Companion diagnostics are codeveloped with targeted agents, ensuring that only patients with the appropriate molecular profile receive the drug.
6. Translating Molecular Data to Clinical Decisions
The workflow typically involves:
- Sample acquisition (biopsy, liquid biopsy, or surgical resection).
- Comprehensive molecular testing (NGS panel, RNAseq, proteomics).
- Bioinformatic analysis to call variants and assess functional impact.
- Multidisciplinary molecular tumor board review.
- Selection of FDAapproved targeted agents or enrollment in clinical trials.
Key challenge: integrating heterogeneous data streams into an actionable report while maintaining turnaround times compatible with treatment planning.
7. Emerging Technologies
Several innovations promise to refine patientspecific therapy further:
- Singlecell sequencing uncovers intratumor heterogeneity and rare resistant clones.
- Spatial transcriptomics maps gene expression to tissue architecture, informing surgical margins.
- CRISPRbased functional screens identify novel vulnerabilities in patientderived organoids.
- Artificial intelligence integrates genomic, clinical, and imaging data to predict response probabilities.
8. Conclusion
The molecular basis of patientspecific therapy rests on a convergent view of genetics, epigenetics, proteomics, and functional biomarkers. By systematically characterizing these layers, clinicians can move beyond onesizefitsall regimens to truly personalized treatment plans. Ongoing advances in highresolution profiling and data integration will continue to expand the therapeutic arsenal, ultimately improving outcomes and reducing toxicity for each individual patient.
